Evidence map›Paper›PMID 37430113›Full record

ArticleNature chemical biology2023

Reconsidering the role of protein glycation in disease.

Marissa N Trujillo, James J Galligan

Abstract read
In one paragraph

Article in Nature chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Glyoxalase 1 is a proadipogenic gene.The Journal of biological chemistry · 2025
    Article
  3. Review
  4. A Chemical Mechanistic Path Leads the Way to Cellular Argpyrimidine.Journal of the American Chemical Society · 2025
    Article
  5. Article
  6. Remodeling and retooling metabolism.Nature chemical biology · 2025
    Article
  7. The chemical language of protein glycation.Nature chemical biology · 2025
    Review
  8. Article
  9. Protein Haptenation and Its Role in Allergy.Chemical research in toxicology · 2024
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marissa N TrujilloDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
James J GalliganDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA. jgalligan@pharmacy.arizona.edu.ORCID 0000-0002-5612-0680

Funding

CHEMISTRY-BIOLOGY INTERFACE TRAINING PROGRAMT32GM008804 · NIGMS · UNIVERSITY OF ARIZONA · PI MONTFORT, WILLIAM R. · 2003 to 2023
$3.9M
Establishing Glyoxalase 2 as a Viable Target for the Treatment of Disease [Equipment Supplement]R35GM137910 · NIGMS · UNIVERSITY OF ARIZONA · PI GALLIGAN, JAMES J · 2020 to 2024
$2.1M
Glyoxalase 1 and its Role in Metabolic SyndromeR01DK133196 · NIDDK · UNIVERSITY OF ARIZONA · PI James J Galligan · 2023 to 2026
$1.8M
NIDDK NIH HHS R01 DK133196NIGMS NIH HHS R35 GM137910NIGMS NIH HHS T32 GM008804
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Maillard ReactionGlycosylation

Identifiers

PMID37430113
PMCPMC10807257

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.